The Misuse of Drugs Act 1971 (Amendment) Order 2016
| Jurisdiction | UK Non-devolved |
| Citation | SI 2016/1109 |
| Year | 2016 |
2016 No. 1109
Dangerous Drugs
The Misuse of Drugs Act 1971 (Amendment) Order 2016
Made 16th November 2016
Coming into force in accordance with article 1
At the Court at Buckingham Palace, the 16th day of November 2016
Present,
The Queen’s Most Excellent Majesty in Council
In accordance with section 2(5) of the Misuse of Drugs Act 19711a draft of this Order has been laid before Parliament on the recommendation of the Advisory Council on the Misuse of Drugs and approved by a resolution of each House of Parliament.
Accordingly, Her Majesty, in exercise of the powers conferred upon Her by section 2(2) of that Act, is pleased, by and with the advice of Her Privy Council, to order as follows:
Citation and commencement
1. This Order may be cited as the Misuse of Drugs Act 1971 (Amendment) Order 2016 and comes into force on the twenty-eighth day after the day on which it is made.
Amendments to the Misuse of Drugs Act 1971
2. The following amendments are made to Schedule 2 to the Misuse of Drugs Act 1971.
3. In Part 2 (which specifies the drugs which are subject to control under that Act as Class B drugs)—
(a) after paragraph 1(c) insert—
“(ca)
“(ca) any compound (not being clonitazene, etonitazene, acemetacin, atorvastatin, bazedoxifene, indometacin, losartan, olmesartan, proglumetacin, telmisartan, viminol, zafirlukast or a compound for the time being specified in sub-paragraph (c) above) structurally related to 1-pentyl-3-(1-naphthoyl)indole (JWH-018), in that the four sub-structures, that is to say the indole ring, the pentyl substituent, the methanone linking group and the naphthyl ring, are linked together in a similar manner, whether or not any of the sub-structures have been modified, and whether or not substituted in any of the linked sub-structures with one or more univalent substituents and, where any of the sub-structures have been modified, the modifications of the sub-structures are limited to any of the following, that is to say—
(i) replacement of the indole ring with indane, indene, indazole, pyrrole, pyrazole, imidazole, benzimidazole, pyrrolo[2,3-b]pyridine, pyrrolo[3,2-c]pyridine or pyrazolo[3,4‑b]pyridine;
(ii) replacement of the pentyl substituent with alkyl, alkenyl...
To continue reading
Request your trial